Biologix is a Dubai-based firm that represents international pharma companies by bringing innovative drugs to market in the Middle East / North Africa (MENA) region. Its GM, Zeina Sfeir Lahoud, discusses the company’s presence in over 17 countries, their 25 years of experience in Saudi Arabia, and the dynamics shaping the largest market in the region, including the fast regulatory approval process in place. With value-based healthcare an increasingly hot topic, she explains how Biologix has moved to sign the first risk-sharing agreement with Saudi Arabia for a spinal muscular atrophy product; the first in the MENA region.
STAY UP TO DATE NEWS & EVENTS
Related EVENTS & NEWS
Biologix Drives Access & Pricing Innovation at World EPA Congress 2025
Biologix at the 4th Middle East Pharmacoeconomics and Drug Policy Summit
Biologix, a leader in rare disease treatment accessibility, played a pivotal role at the 4th Middle East Pharmacoeconomics and Drug Policy Summit in Dubai.
Biologix at the 7th Omani Society of Hematology & 16th Arab Transfusion Medicine Forum
